Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia

What is it about?

There is an urgent need for markers to identify treatment resistance in schizophrenia at an early stage in order to reduce delays in effective treatment. We demonstrate the potential of neuromelanin MRI as a non-invasive marker for treatment resistance in first episode schizophrenia and we provide further evidence for dopaminergic differences between non-responders and responders.

Featured Image